BioIntelliSense develops continuous health monitoring technology for Remote Patient Monitoring (RPM), combining FDA-cleared wearable devices with a medical-grade Data-as-a-Service platform. The system is designed to support clinical care across settings - from acute hospital wards to the patient's home - by capturing multi-parameter vital signs, physiological biometrics, and symptomatic events without interruption.
The company's product ecosystem spans hardware, connectivity, and software. The BioButton® is an FDA-cleared wearable that passively records vital signs and biometric data. BioHub™ gateway devices manage connectivity between the wearable and the cloud, while BioMobile™ applications provide mobile access for patients. On the data and clinical side, BioCloud™ serves as the medical-grade DaaS backbone - capturing, storing, and delivering continuous multi-parameter data - and BioDashboard™ presents clinicians with high-resolution vital sign trends and data-driven insights to support decision-making.
The platform is built around early detection of patient deterioration. Clinical evidence cited by the company points to reductions in unplanned ICU admissions, rapid response team activations, and average hospital length of stay. The system is said to identify deterioration often hours earlier than traditional intermittent monitoring approaches.
BioIntelliSense operates across acute care and post-acute settings, with its technology applicable to hospital-based clinical teams as well as home health workflows. The technical stack spans physiological sensing, edge connectivity, cloud data services, and clinical intelligence - making it a cross-disciplinary environment covering embedded hardware, cloud infrastructure, and health data systems.
